Top of this page
Skip navigation, go straight to the content

An attractive late stage
pipeline

For a medium-sized biopharma company, UCB has an attractive pipeline of large and small molecules, many in late-stage development.
Some of these are intended to strengthen the company's positions in disease areas such as epilepsy. Others could take the company into new areas of severe disease such as systemic lupus erythematosus and osteoporosis.

UCB believes that this pipeline possesses immense potential for future growth as well as improving the quality of life for patients.

    Here is an overview of the major projects currently being developed by UCB:

    Small molecule drug / NCE

    Small molecule drug / NCE

    Antibody-based drug / NBE

    Antibody-based drug / NBE



    CNS Indications Phase 1 Phase 2 Phase 3 Filed
    Keppra®epilepsy - adjunctive therapy (Japan)
    		phase 4
    Neupro®
    		advanced Parkinson's disease (U.S.)
    		phase 4
    Neupro®
    		restless legs syndrome (U.S.)
    		phase 4
    Xyrem®
    		fibromyalgiaphase 3
    brivaracetamepilepsy - adjunctive therapy
    		phase 3 half
    Vimpat®epilepsy - monotherapy (U.S.)
    		phase 3 half
    Vimpat®epilepsy adjunctive therapy 1
    		phase 2
    Vimpat®epilepsy adjunctive therapy PGTC 2
    		phase 2
    UCB 2892central nervous system
    		phase 1 half
    Immunology Indications Phase 1 Phase 2 Phase 3 Filed
    Cimzia®ankylosing spondylitisphase 3 half
    Cimzia®psoriatic arthritisphase 3 half
    Cimzia®juvenile rheumatoid arthritisphase 3 half
    Cimzia®rheumatoid arthritis (Japan)phase 3 half
    epratuzumabsystemic lupus erythematosusphase 2
    CDP7851fracture healingphase 2 half
    CDP7851post-menopausal osteoporosisphase 2 half
    CDP6038auto-immune diseasesphase 1 half
    CDP7657systemic lupus erythematosusphase 1 half
    1. Paediatric 2-17 years
    2. Primary generalised tonic clonic